Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Human-derived mesenchymal stem cell conditioned medium for chronic pain
jRCT1051220092Recruiting
- Sponsor
- Seihoku Clinic
- Start
- Aug 2022
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Open-label, single-arm trial of human-derived mesenchymal stem cell conditioned medium in chronic pain, sponsored by Seihoku Clinic. Primary endpoints: Subjective symptoms, Effect of pain on daily life and 6 more. Started Aug 2022; status: recruiting.
02
Drugs
human-derived mesenchymal stem cell conditioned medium
03
Conditions
chronic pain
Beyond the preview
Go deeper on jRCT1051220092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1051220092.